|Bid||0.0000 x 800|
|Ask||0.0000 x 900|
|Day's range||0.0680 - 0.0698|
|52-week range||0.0500 - 0.7200|
|Beta (5Y monthly)||1.35|
|PE ratio (TTM)||N/A|
|Earnings date||06 Nov 2023 - 10 Nov 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||0.50|
Horizon Therapeutics (HZNP) reports lower-than-expected first-quarter 2023 results as it misses the Zacks Consensus Estimates for both revenues and earnings.
Anixa Biosciences (ANIX) announces positive top-line data from its phase Ia study evaluating the safety of its breast cancer vaccine. However, the stock plunges 25% in the absence of efficacy reports.
The FDA grants Fast Track Designation to Agenus' (AGEN) phase II study evaluating the botensilimab/balstilimab combination in non-MSI-H colorectal cancer patients. The stock jumps 16% following the news.